Evidence map›Paper›PMID 24500400›Full record

ArticleGenes and immunity

IL-15 prolongs CD154 expression on human CD4 T cells via STAT5 binding to the CD154 transcriptional promoter.

R M Lowe, A Genin, N Orgun, R Q Cron

Open access · bronzeAbstract read
In one paragraph

Article in Genes and immunity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Hydroxychloroquine inhibits CD154 expression in CD4Arthritis research & therapy · 2017
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

R M Lowe1] Department of Pediatrics, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA [2] Division of Rheumatology, The Children's Hospital of Alabama, Birmingham, AL, USA.
A GeninDepartment of Pediatrics, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
N OrgunFred Hutchinson Cancer Research Center, Seattle, WA, USA.
R Q Cron1] Department of Pediatrics, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA [2] Division of Rheumatology, The Children's Hospital of Alabama, Birmingham, AL, USA.
University of Alabama at Birmingham · USChildren's of Alabama · USFred Hutch Cancer Center · US

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
ROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5M
Regulation of CD154 in Systemic Lupus ErythematosusR01AR048257 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CRON, RANDALL Q · 2003 to 2007
$1.6M
New Methods for Monitoring Treating for OsteoporosisR01AR048527 · NIAMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI BRAND, RICHARD · 2002 to 2003
$371k
Role of NFAT Proteins in CD154 Gene Regulation and LupusR21AR049335 · NIAMS · CHILDREN'S HOSPITAL OF PHILADELPHIA · PI CRON, RANDALL Q · 2002 to 2003
$170k
NIAID NIH HHS P30 AI027767NIAMS NIH HHS P30 AR048311NIAMS NIH HHS R01 AR048257NIAMS NIH HHS R01 AR048527NIAMS NIH HHS R01-AR-48527NIAMS NIH HHS R21 AR049335NIAMS NIH HHS R21-AR-49335
6 · The paper itself

Abstract

Activation-induced CD154 expression on CD4 T cells is prolonged in systemic lupus erythematosus, but the mechanism(s) for its dysregulation are unknown. The studies reported herein demonstrate that interleukin-15 (IL-15) is capable of prolonging CD154 expression on phytohemagglutinin (PHA)-activated CD4 T cells. As IL-15 signals through signal transducer and activator of transcription 5 (STAT5), predicted STAT5 binding sites in the human CD154 transcriptional promoter were identified, and STAT5 binding to the proximal CD154 promoter in vitro and in vivo following primary CD4 T-cell activation was demonstrated. Moreover, overexpression of wild-type STAT5 in primary human CD4 T cells augmented CD154 transcription, whereas overexpression of a dominant-negative (DN) STAT5 protein inhibited CD154 transcription. Mutation of the most proximal STAT5 binding site in the CD154 promoter resulted in diminished DNA binding and reduced CD154 transcriptional activity. Interestingly, STAT5-specific small interfering RNA inhibited CD154 surface expression at 48 but not 24 h after T-cell activation. Thus, these findings provide some of the first evidence to support a possible mechanistic link to explain how the overexpression of IL-15 observed in lupus patients may be involved in the prolonged expression of CD154 that has also been observed on lupus CD4 T cells.

Indexed as

Promoter Regions, GeneticTranscriptional ActivationAdolescentBinding SitesCase-Control StudiesCD40 LigandCD4-Positive T-LymphocytesChildFemaleGene Expression RegulationGenes, ReporterHumansInterleukin-15Lupus Erythematosus, SystemicMutationProtein BindingCD40 LigandInterleukin-15STAT5 Transcription Factor

Identifiers

PMID24500400
PMCPMC4133980
OpenAlexW2050792186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.